TrialCell reports. Medicine2025

Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study.

Liangyu Bie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.